Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Itepekimab by Regeneron Pharmaceuticals for Bronchiectasis: Likelihood of Approval
Itepekimab is under clinical development by Regeneron Pharmaceuticals and currently in Phase II for Bronchiectasis. According to GlobalData, Phase II...
Risk adjusted net present value: What is the current valuation of Sanofi's Itepekimab?
Itepekimab is a monoclonal antibody commercialized by Sanofi, with a leading Phase III program in Chronic Obstructive Pulmonary Disease (COPD)....
Risk adjusted net present value: What is the current valuation of Sanofi's Itepekimab?
Itepekimab is a monoclonal antibody commercialized by Sanofi, with a leading Phase III program in Chronic Obstructive Pulmonary Disease (COPD)....